STRUCTURAL VARIATION IN THE HUMAN GENOME

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

whitePaper | June 8, 2022

Sequencing of human genomes is fast becoming an affordable technology for general consumer.

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.

whitePaper | March 18, 2022

Fungi are usually seen by the wood used only as destroyers or parasites. Material infestation should be avoided as far as possible for wood preservation reasons.

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).